KRP-105
KRP-105 is a potent, highly selective, and orally effective PPAR alpha (EC50 = 8 nM) agonist. KRP-105 can significantly reduce serum triglyceride, total cholesterol, and non high density lipoprotein cholesterol levels. KRP-105 can be used for research on metabolic diseases such as dyslipidemia.
For research use only. We do not sell to patients.
- CAS No.: 876145-69-6
- Formula: C23H22ClN3O3S
- Molecular Weight:455.96
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
PPARα |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO-K1 | EC50 |
0.008 μM
Compound: (S)-4f, KRP-105
|
Transactivation of human PPARalpha expressed in CHO-K1 cells
Transactivation of human PPARalpha expressed in CHO-K1 cells
|
[PMID: 22133631] |
| CHO-K1 | EC50 |
3 μM
Compound: (S)-4f, KRP-105
|
Transactivation of human PPARdelta expressed in CHO-K1 cells
Transactivation of human PPARdelta expressed in CHO-K1 cells
|
[PMID: 22133631] |
| CHO-K1 | EC50 |
9.6 μM
Compound: (S)-4f, KRP-105
|
Transactivation of human PPARgamma expressed in CHO-K1 cells
Transactivation of human PPARgamma expressed in CHO-K1 cells
|
[PMID: 22133631] |
| HEK-293T | EC50 |
5 nM
Compound: SC-1
|
Agonist activity at GAL4-tagged PPARalpha ligand-binding domain (unknown origin) expressed in HEK293T cells incubated for 16 to 19 hrs by beta-lactamase reporter gene assay
Agonist activity at GAL4-tagged PPARalpha ligand-binding domain (unknown origin) expressed in HEK293T cells incubated for 16 to 19 hrs by beta-lactamase reporter gene assay
|
[PMID: 25491112] |
Chemical Information
-
CAS No. 876145-69-6
-
Molecular Weight 455.96
-
Formula C23H22ClN3O3S
-
SMILES
OC(C1=CC=CC(N(CCC2)C[C@H]2NC(C3=C(C)N=C(C4=CC=C(C=C4)Cl)S3)=O)=C1)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)